Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

Kim C. Ohaegbulam(Albert Einstein College of Medicine), Amer Assal(Montefiore Medical Center), Eszter Lázár‐Molnár(University of Utah), Yu Yao(Fudan University), Xingxing Zang(Albert Einstein College of Medicine)
Trends in Molecular Medicine
October 30, 2014
10.1016/j.molmed.2014.10.009
Cited by 837Open Access
Full Text

Abstract

Related Papers

Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Yasumasa Ishida, Yasutoshi Agata, Kei‐ichi Shibahara et al.|The EMBO Journal|1992|3.2k
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer, Charles G. Drake, Ira Wollner et al.|Journal of Clinical Oncology|2010|2.9k
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
Haidong Dong, Gefeng Zhu, Koji Tamada et al.|Nature Medicine|1999|2.5k
The PD‐1 pathway in tolerance and autoimmunity
Loise M. Francisco, Peter T. Sage, Arlene H. Sharpe|Immunological Reviews|2010|2.3k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert, Antoni Ribas, Jedd D. Wolchok et al.|The Lancet|2014|1.8k